Safety and Efficacy of the GORE® Septal Occluder to Treat Ostium Secundum Atrial Septal Defects

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 400 participants.

Also called NCT01711983

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 400 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01711983
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01711983. Allocation not applicable; no masking; primary purpose treatment. Start 2012-10 (actual); primary completion 2018-11-26 (actual). Results posted on 2020-08-21.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety and Efficacy of the GORE® Septal Occluder to Treat Ostium Secundum Atrial Septal Defects
Condition
Septal Defect, Atrial
Intervention (Device)
GORE® CARDIOFORM Septal Occluder
Lead sponsor
W.L.Gore & Associates (class: industry)

Record details

Record id
cardio:ct-nct01711983
Content hash
7fed58190e919c9ef55669e163666dba88a65316c37ba92a4f5f7a44bff87e4e